At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Immunosuppressive Therapy +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Feasibility Study of Discontinuation Versus Continuation of Immunosuppressive Therapy (IST) in Patients With Chronic Graft Versus Host Disease (GVHD)
In Brief
A Phase 2 clinical trial evaluating Immunosuppressive Therapy and Survey Administration for Chronic Graft Versus Host Disease. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease. Continuation of immunosuppressive treatment may prevent graft-versus-host disease worsening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft Versus Host Disease
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartJun 2018
Primary CompletionMay 2020
Study CompletionMar 2021
TodayJul 2026
First PostedMar 30, 2018
Enrollment StartJun 6, 2018
Primary CompletionMay 14, 2020
Study CompletionMar 3, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.3 years ago
Interventions
Immunosuppressive Therapybiological
Discontinued IST
Immunosuppressive Therapybiological
Continued IST
Survey Administrationother
Ancillary studies